Rapid weight loss from GLP-1 receptor agonists often includes substantial reductions in skeletal muscle mass alongside fat loss

Overview Debates Related claims Topics

GLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling points

Rural farming populations in northern Rwanda consuming high-carbohydrate diets display virtually no cases of obesity

In the United States, approximately 42% of adults are classified as obese

Approximately 50% to 60% of patients prescribed GLP-1 receptor agonist medications discontinue treatment within a few years

Over 1,000 distinct genetic loci have been associated with obesity risk in human genome-wide association studies

Populations in northern Rwanda experience sharp increases in obesity and type 2 diabetes following migration into urban environments

Adult obesity rates in the United States quadrupled between the mid-twentieth century and the 2020s

Approximately 72% of adults in the United States are classified as either overweight or obese based on body mass index

Heritability studies estimate that genetic variation explains between 30% and 70% of population-level body weight variation

Known obesity-associated genetic variants collectively account for between 6% and 17% of total variance in body weight

More than 20 pharmaceutical companies reached agreements with the Trump administration pledging not to charge significantly higher drug prices in the United States than in other nations

Bayer co-markets a blood-thinner medication with Johnson & Johnson that faces generic market competition

Pharmaceutical companies pulled drugs or delayed launches in European markets to avoid lowering domestic United States drug prices under reference-pricing deals

Bayer's drug San Arbo is designed to prevent repeat strokes without significantly increasing a patient's bleeding risk compared to standard blood thinners

The United States Food and Drug Administration approved Bayer's blood thinner San Arbo to decrease the risk of dangerous internal bleeding

Market research firm GlobalData recorded a 27% decline in new European pharmaceutical launches over a 17-month period

Under Attorney General Ken Paxton, the Texas Attorney General's office filed legal challenges against DACA and the sale of mifepristone

Forty-five percent of United States adolescents are classified as overweight or obese

An Environmental Protection Agency assessment on glyphosate safety was discarded in court after evidence showed chemical company Bayer ghostwrote research sections

Department of Justice attorney Sarah Harris, previously employed at Bayer's primary law firm, drafted the brief supporting glyphosate liability protection before the Supreme Court